Alamar Biosciences says Lancet Neurology study tracks 130 plasma biomarkers in real-world lecanemab-treated Alzheimer’s patients
ALMR•A Lancet Neurology study tracked 130 plasma biomarkers in real-world Alzheimer’s patients receiving lecanemab. Its findings showed amyloid clearance signals diverged from markers tied to later cognitive decline, with biomarker shifts varying across patients.
1. Study findings
The published longitudinal study tracked plasma biomarkers during lecanemab treatment in real-world patients with Alzheimer’s disease. Its conclusion was that amyloid clearance signals diverged from markers tied to later cognitive decline, suggesting treatment effects did not align with clinical response.
2. Responses varied
Biomarker shifts varied across patients during dosing, indicating heterogeneous biological responses that could affect how therapy is monitored in practice.
